RecruitingNot Applicable

Life-2023-02 Esophagogastric Variceal Bleeding

China33 participantsStarted 2023-08

Plain-language summary

Study on the efficacy of the growth inhibitors after endoscopic treatment of acute esophagogastric variceal bleeding

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * acute esophagogastric bleeding with hepatic cirhosis; * stable status (no active bleeding) Exclusion Criteria: * endoscopic test limitation; * previous acute esophagogastric bleeding treatment history; * ICU; * pregnant; * Immunity disabled;

What they're measuring

rebleeding rate after the endoscopic treatment in Group A at 1 month

Timeframe: 1 month after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group A at 3 months

Timeframe: 3 months after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group A at 6 months

Timeframe: 6 months after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group B at 1 month

Timeframe: 1 month after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group B at 3 months

Timeframe: 3 months after the endoscopic treatment

rebleeding rate after the endoscopic treatment in Group B at 6 months

Timeframe: 6 months after the endoscopic treatment

Trial details

NCT IDNCT06011980

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-05-10

Contact for this trial

WEI WEI

15267175186 wwze@zju.edu.cn

View on ClinicalTrials.gov More Acute Esophageal Variceal Hemorrhage trials